Gene Therapy Latest News | Experimental Gene Therapy Studies

CSL Behring Acquires AMT-061, Hem B Gene Therapy in Phase 3 Trial

06 May 2021

FDA Lifts Hold on uniQure’s Hemophilia B Gene Therapy Program

27 April 2021

Criteria for Gene Therapy Trials Can Exclude Many With Severe Hemophilia

30 April 2021

Hemophilia B Gene Therapy AMT-061 Unlikely to Have Caused Liver Tumor

01 April 2021

Roctavian, Potential Hemophilia A Gene Therapy, Get Fresh FDA Support
11 March 2021
Gene Therapy SPK-8016 Shows Early Promise for Severe Hemophilia A
08 February 2021
Roctavian, Hem A Gene Therapy, Sustains Drop in Bleeding Rates, Phase 3 Data Show
13 January 2021
BioMarin Announces Positive Phase 3 Gene Therapy Trial Results in Adults with Severe Hemophilia A; Study Met All Primary and Secondary Efficacy Endpoints in One-Year Data Set
10 January 2021

I agree with the Terms and conditions and the Privacy policy

About

Supported by educational grants from Bayer, BioMarin, CSL Behring, Freeline Therapeutics Limited, Pfizer Inc., Spark Therapeutics, and uniQure, Inc.

Essential SSL